Literature DB >> 23942524

Critical role of interleukin-5 in the development of a mite antigen-induced chronic bronchial asthma model.

Hiroki Shimizu1, Yasushi Obase, Shigeki Katoh, Keiji Mouri, Yoshihiro Kobashi, Mikio Oka.   

Abstract

OBJECTIVE AND
DESIGN: Asthma is associated with eosinophilic airway inflammation and characterized by enhanced airway sensitivity. Interleukin (IL)-5 plays an important role in the pathogenesis of asthma. The involvement of IL-5 receptor-mediated cellular signals in the pathogenesis of a mite antigen-induced chronic asthma model was investigated.
SUBJECTS: In this study, 48 female C57BL/6J (WT) mice and IL-5 receptor-deficient (IL-5RKO) mice were used. TREATMENT: Mite antigen (50 μl) was intranasally administered 13 times to WT and IL-5RKO mice.
METHODS: Airway hypersensitivity (Mch PC200) and specific antigen exposure tests were performed, and lung tissue, bronchoalveolar lavage fluid (BALF), and blood were collected to investigate the asthma pathology and differences in the local pulmonary levels of cytokines and chemokines.
RESULTS: Airway sensitivity was enhanced and antigen-specific airway resistance was increased in WT mice. In addition, the number of eosinophils and Th2 cytokine levels in the BALF were increased. In contrast, IL-5RKO mice did not acquire the asthma pathology, such as antigen-specific airway resistance and eosinophilic airway inflammation. Mch PC200 was significantly correlated with cysteinyl leukotriene levels in WT mice.
CONCLUSION: These findings suggested that both IL-5 induced eosinophils and cysteinyl leukotrienes are involved in the pathology of this mite antigen-induced chronic asthma model.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23942524     DOI: 10.1007/s00011-013-0651-y

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  21 in total

Review 1.  Mechanisms of eosinophil-associated inflammation.

Authors:  G J Gleich
Journal:  J Allergy Clin Immunol       Date:  2000-04       Impact factor: 10.793

Review 2.  Asthma. From bronchoconstriction to airways inflammation and remodeling.

Authors:  J Bousquet; P K Jeffery; W W Busse; M Johnson; A M Vignola
Journal:  Am J Respir Crit Care Med       Date:  2000-05       Impact factor: 21.405

Review 3.  Analysis of montelukast in mild persistent asthmatic patients with near-normal lung function.

Authors:  N Barnes; L X Wei; T F Reiss; J A Leff; S Shingo; C Yu; J M Edelman
Journal:  Respir Med       Date:  2001-05       Impact factor: 3.415

Review 4.  Molecular basis for selective eosinophil trafficking in asthma: A multistep paradigm.

Authors:  A J Wardlaw
Journal:  J Allergy Clin Immunol       Date:  1999-11       Impact factor: 10.793

5.  Accumulation of CXCR3-expressing eosinophils and increased concentration of its ligands (IP10 and Mig) in bronchoalveolar lavage fluid of patients with chronic eosinophilic pneumonia.

Authors:  Shigeki Katoh; Kiyoyasu Fukushima; Nobuhiro Matsumoto; Naomi Ehara; Kiyoshi Matsumoto; Akira Yamauchi; Mitsuomi Hirashima
Journal:  Int Arch Allergy Immunol       Date:  2005-06-13       Impact factor: 2.749

6.  CD44 is critical for airway accumulation of antigen-specific Th2, but not Th1, cells induced by antigen challenge in mice.

Authors:  Shigeki Katoh; Osamu Kaminuma; Takachika Hiroi; Akio Mori; Takayuki Ohtomo; Sachie Maeda; Hiroki Shimizu; Yasushi Obase; Mikio Oka
Journal:  Eur J Immunol       Date:  2011-09-19       Impact factor: 5.532

7.  Allergen-induced airway inflammation and bronchial responsiveness in interleukin-5 receptor alpha chain-deficient mice.

Authors:  H Tanaka; N Kawada; T Yamada; K Kawada; K Takatsu; H Nagai
Journal:  Clin Exp Allergy       Date:  2000-06       Impact factor: 5.018

8.  Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group.

Authors:  T F Reiss; P Chervinsky; R J Dockhorn; S Shingo; B Seidenberg; T B Edwards
Journal:  Arch Intern Med       Date:  1998-06-08

Review 9.  Mouse models of allergic asthma: acute and chronic allergen challenge.

Authors:  Anthony T Nials; Sorif Uddin
Journal:  Dis Model Mech       Date:  2008 Nov-Dec       Impact factor: 5.758

10.  Mepolizumab and exacerbations of refractory eosinophilic asthma.

Authors:  Pranabashis Haldar; Christopher E Brightling; Beverley Hargadon; Sumit Gupta; William Monteiro; Ana Sousa; Richard P Marshall; Peter Bradding; Ruth H Green; Andrew J Wardlaw; Ian D Pavord
Journal:  N Engl J Med       Date:  2009-03-05       Impact factor: 91.245

View more
  5 in total

1.  Hyper-reactive cloned mice generated by direct nuclear transfer of antigen-specific CD4+ T cells.

Authors:  Osamu Kaminuma; Kazufumi Katayama; Kimiko Inoue; Mayumi Saeki; Tomoe Nishimura; Noriko Kitamura; Yusuke Shimo; Soichi Tofukuji; Satoru Ishida; Narumi Ogonuki; Satoshi Kamimura; Mami Oikawa; Shigeki Katoh; Akio Mori; Michitaka Shichijo; Takachika Hiroi; Atsuo Ogura
Journal:  EMBO Rep       Date:  2017-05-02       Impact factor: 8.807

Review 2.  Key mediators in the immunopathogenesis of allergic asthma.

Authors:  Sannette Hall; Devendra K Agrawal
Journal:  Int Immunopharmacol       Date:  2014-06-13       Impact factor: 4.932

3.  Participation of Leukotrienes in the Immune Modulation of Oral Tolerance.

Authors:  Sandra R P de Oliveira; Auro Nomizo; Fabiani G Frantz; Lúcia H Faccioli; Ana Paula Keller de Matos; Emanuel Carrilho; Ana Afonso; Fernanda de Freitas Anibal
Journal:  Front Microbiol       Date:  2017-02-21       Impact factor: 5.640

Review 4.  Role of CD4+ T Cells in Allergic Airway Diseases: Learning from Murine Models.

Authors:  Kento Miura; Kimiko Inoue; Atsuo Ogura; Osamu Kaminuma
Journal:  Int J Mol Sci       Date:  2020-10-11       Impact factor: 5.923

Review 5.  IL-4-C-590T locus polymorphism and susceptibility to asthma in children: a meta-analysis.

Authors:  Xiaosheng Jin; Jisheng Zheng
Journal:  J Pediatr (Rio J)       Date:  2020-08-09       Impact factor: 2.990

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.